fbpx JLABS Company News | JLABS

News


In the media

J&J Innovation announces QuickFire Challenge winner

By Staff Report

Read full story
Other news

Want to know more about the JLABS Portfolio?

By JLABS

Read full story

Lung Cancer Innovation QuickFire Challenge

Jlab_Quickfire-2018-06-12
lung cancer
Challenge ended

$750,000 (¥4.7M) in Grants + Residency + Mentoring

Surgical Oncology
Therapeutics

                        点击这里阅读中文

Awardees

Lung%20Cancer%20Innovation%20QFC%20Awardees.png

 

DNX Biopharmaceuticals

 

DNX Bio is a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of patients with life-long diseases. Founded in 2014 and headquartered in Irvine, CA, USA, DNX is pursuing the development of new therapeutic proteins utilizing a 21st century, half-life extension platform technology known as PASylation, which is in-licensed from XL-protein GmbH. XLp has granted DNX a worldwide exclusive license under its patents and know-how related to the PASylation technology to develop and commercialize several PASylated products.

 

Hawkeye Bio

 

Hawkeye Bio was launched in 2018 in California to commercialize novel, clinically validated breath analytics for the detection of lung cancer. Lung cancer is the leading cause of cancer deaths among both men and women[1]. Lung cancer often has no symptoms until it has metastasized, because there are few specialized nerves (pain receptors) in the lungs. Lung cancer is diagnosed late 84% of the time, when treatment options are more limited. Despite progress in biomarker discovery and targeted therapy, lung cancer mortality remains unacceptably high worldwide. Hawkeye’s mission is lung cancer interception to bring about a solution to this problem.

 

NE Scientific

 

NE Scientific is a Boston-based startup company developing a surgical guidance software for supporting physicians in targeting tissues during the percutaneous ablation of liver and lung tumors. The Accublate (TM) guidance software simulates in real-time the physics taking place during the ablation and determines the ablation volume in a patient-specific way. This information is generated intraoperatively and overlaid to CT images of the patient, helping the physician in achieving a complete treatment of all malignant tissues.

[1]HawkeyeBio.com, 2019

The Challenge

Image Paragraph

The average person breathes in 432 liters of oxygen every single day, a vital component in sustaining the trillions of cells in the body. Humans can survive just a few minutes without oxygen.  To that end, it is essential that we protect our lungs.  

Is there a way to cleanse the lungs after exposure to carcinogens much like a toothbrush cleanses the mouth after eating? Is there a way to shield the lungs from carcinogens much like sunscreen shields us from damaging UV exposure?  These are a few of the provocative ideas Johnson & Johnson Innovation hopes to trigger through the Lung Cancer Innovation QuickFire Challenge. 

Lung cancer is a major cause of global morbidity and mortality with approximately 1.6 million deaths globally each year.  Unlike other diseases, lung cancer is caused by prolonged environmental exposure to carcinogens that overwhelm a human’s natural defenses and result in inflammation, genomic changes and ultimately tumor growth.  Although a global epidemic, it is unclear what makes one individual over another more susceptible to developing lung cancer.  

Johnson & Johnson (China) Investment Ltd. and Johnson & Johnson Innovation LLC are committed to prioritizing lung health.  How do we leverage the totality of science and technology to achieve comprehensive lung health -  to ultimately prevent, intercept and cure lung cancer?

Up to three innovators with the best ideas, technologies, or solutions that improves human healthcare related to preventing, intercepting or curing lung cancer will be awarded up to a total of $750,000 in grants, a voucher for one year of residency at JLABS @ Shanghai (optional), including a laboratory bench, workstation and access to the JLABS community, and mentorship from Johnson & Johnson Innovation and/or its affiliates.

Reward

Up to $750,000 (¥4,775,850) in total grants 
  • 1 year residency at JLABS @ Shanghai (Optional)
  • Mentoring & coaching from experts from Johnson & Johnson Innovation and/or its affiliates

Areas of Interest

We encourage applications from innovators working on all aspects of lung health, including solutions focused on Lung Cancer:

  • Prevention: Approaches to identify risks and for warding off onset of lung cancer
  • Interception: Arrest lung cancer as it develops, prior to clinical onset
  • Cures: Completely eliminate presence of lung cancer and reverse damage to restore full health

Please keep in mind that no idea is too big or too early for consideration. Applications that clearly describe a concept or path forward to achieve these goals will also be considered during evaluation.  

We are interested in applications addressing the full spectrum of lung health. Specific areas of interest include, but are not limited to: 

  • To develop approaches to reduce, prevent, or protect from exposure to respiratory carcinogen, including novel approaches to smoking cessation 
  • To develop approaches to measure the exposure to and biological effect from respiratory carcinogens
  • To develop diagnostics/biomarkers to detect pre-cancers or early-stage malignant lesions
  • To develop approaches, including surgical, medical, behavioral, digital or others, to prevent or intercept lung carcinogenesis
  • To discover new tools for diagnosis and extirpation of curable lung cancers
  • To develop new treatments or treatment modalities for the cure of lung cancer

Approaches should include the following areas:

  • Pharmaceuticals
  • Consumer products
  • Medical devices
  • Global public health
  • Health technologies
  • Cross-sector initiatives – an integration of one or more the aforementioned areas of focus 

Application Process

Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Potential impact
  • Uniqueness of solution & level of competition in current market
  • Quality & feasibility of technology
  • Team credibility & capabilities
  • Idea submission outlines interest in the innovation ecosystem in Shanghai (optional)

Timeline

June 14, 2018 (China Time)
Applications Open
September 21, 2018 (China Time)
Submission Deadline
Spring 2019
Winner Announcement at JLABS @ Shanghai Launch

Apply Now


Don’t miss the deadline

Why this challenge matters to us

We believe a good idea can come from anywhere, and it’s our goal to find new and innovative technologies that provide solutions to patients from across the world. Working together, we can spark the next great idea that will change the trajectory of health.

FAQs

 

Q: What if I’m having trouble accessing the portal/website?

A: Make sure your browser is up to date and accepting cookies. You can contact customer service at [email protected] if you are having technical difficulties as well.

 

Q: Is residency at JLABS @ Shanghai required?

A: No. Residency is encouraged but optional.

 

Q: Do I need to reside in Shanghai or a Chinese entity in order to apply?

A: No. We are seeking innovations globally.

 

Q: For prizes involving residency at JLABS, what does that entail and for how many people?

A: For challenges involving residency at JLABS, that entails 1 lab bench and 1 workstation (desk) for 2 people maximum. If you have more employees, additional footprint can be rented.

 

Q: For prizes involving residency at JLABS, are there any expenses not covered by JLABS?

A: Each applicant will be required to submit to a background check, which is subject to a minimal fee.  We also collect a deposit that is refundable at the end of the lease term. There may be other expenses, but this will be dependent on the work that the company is doing in JLABS.  There may also be fees associated with EH&S waste, specialty equipment, printing and phone calls.

 

Q: Will JLABS pay for my living costs, relocation or visas?

A: No, any additional fees and paperwork are up to the winner.

 

Q: Can I submit supporting documents (for example a video) as part of my application? 

A: You will have the opportunity and are encouraged to upload supporting materials such as slide decks, research papers, and videos as part of your application. You may submit a video along with your typed responses. Maximum length is 2 minutes.

 

Q: Is it ok if some of the information I submit is confidential?

A: Do not submit confidential information. Only non-confidential information should be submitted and anything you submit will be treated as non-confidential.

 

Q: What happens with IP (Intellectual Property)?

A: As this is a no strings attached arrangement, JLABS does not acquire any IP.  Any IP creation and/or protection remains the sole responsibility of the inventors.

 

Q: Is a patent required to apply?

A: No, a patent is not required to apply.  However, you should not submit any information that you wish to keep confidential or that may negatively impact upon the future patentability of your invention.

 

Q: What kind of science / technology is appropriate for the Challenges? 

A: We encourage all to apply. Find out more about what areas we desire to explore here: https://www.jnjinnovation.com/partnering

 

Q: Who is eligible to apply?

A: Each Challenge has its own terms & conditions that can be found prior to filling out the application.

 

Q: What are the specific criteria for application?

A:  Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Potential impact
  • Uniqueness of solution & level of competition in current market
  • Quality & feasibility of technology
  • Team credibility & capabilities
  • Idea submission outlines interest in the innovation ecosystem in Shanghai (optional)

 

Q: Who can I contact if I have questions about the Challenges or the application process?

A: Please contact [email protected] with any questions.

 

Q: Where do I apply? And do I have to complete the application in one sitting?

A: Apply at https://jlabs.jnjinnovation.com/form/lung-qfc-apply. You are able to save your work and log back in to finish at a later time if needed.

About Johnson and Johnson Innovation, JLABS

Picture1.png

 

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.

JLABS currently has locations in innovation hot spots across the world and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto. New JLABS in NYC and Shanghai have been announced, and in February 2018, the Belgium-based JLINX incubator began transitioning into a JLABS, making this the first JLABS in Europe.  For more information about JLABS, please visit jlabs.jnjinnovation.com.

About Johnson & Johnson (China) Investment Ltd

Picture1_0.png

 

 

 

 

强生公司

强生是全球业务分布广泛、综合性的跨国医疗保健企业,业务涉及消费品、制药、医疗器材三大领域,1985年在华创立了第一家合资企业。强生遵循企业信条的价值观,致力于践行“关爱全世界,关注每个人”的健康愿景,以领先的科技研发创造创新的理念、产品和服务,为改善人类健康和福祉而不懈努力。每天,强生遍布世界各地的员工,与他们的合作方一起,为全球消费者和病患带来更健康、更快乐、更长寿的生活。

 

 


 

Other news

Melinda Richter appointed as the new Vice Chair of the California Life Sciences Association

By CLSA Press Release

Read full story

PExA

PExA AB is a Swedish start-up company that has developed a breakthrough technology enabling
collection of biomaterial from the small airways with potential in discovery of respiratory biomarkers

Focus area
Diagnostics

JLABS @ TMC QuickFire Challenge

JLABS @ TMC QuickFire Challenge
Challenge ended

Residency at JLABS

Consumer Health
Therapeutics

Winners

Image paragraph

Developing next-generation surgical adhesives based on polyurethane, which permit quick and safe wound closure, topically as well as inside the human body.

Image paragraph

Aortix is a heart pump implanted without surgery, designed from the ground-up as a safe and effective treatment for chronic heart failure which affects one in five adults in the United States.

Image paragraph

High-throughput antibody discovery platform for breast and other cancers focused on identifying therapeutics targeted at novel antigens induced by the tumor microenvironment. 

Alterna Therapeutics, Inc.

Developing new therapeutics to treat diabetes and obesity.

The Challenge

In honor of the upcoming Grand Opening of JLABS @ TMC, Johnson & Johnson Innovation has launched a QuickFire Challenge to award new game-changing early-stage innovation companies with the use of a bench, workstation and access to the JLABS @ TMC community for one year.

Latin America QuickFire Challenge

Latin America QuickFire Challenge
Challenge ended

Residency at JLABS

Therapeutics

Winners

Image paragraph

Focused on the production of recombinant proteins from the Zika virus capsid that could be used for isolating or developing anti-Zika monoclonal antibodies, which may be used to treat or reduce the viral load of infected individuals.

The Challenge

As part of the innovation forum for Latin America, Johnson & Johnson Innovation has committed to award one new game-changing early-stage innovation company from Latin America access to the Johnson & Johnson Innovation, JLABS community for six months through participation in a QuickFire Challenge. The JLABS QuickFire Challenge for Latin America is to support ideas to trigger health innovation from the Latin America region.

JLABS @ Toronto QuickFire Challenge

JLABS @ Toronto QuickFire Challenge
Challenge ended

Residency at JLABS

Consumer Health
Digital Health
Therapeutics

Winners

Image paragraph

A4i is a digital health innovation company that provides clinically-proven mobile interventions to significantly enhance treatment engagement and quality of life for individuals with psychosis and other major mental health challenges.

Image paragraph

An innovative gene therapy company focused on immune-oncology and rare diseases.

Image paragraph

Developing novel therapeutics for metastatic cancers employing a comprehensive approach to reverse the metastatic state of tumor cells.

Image paragraph

Achieving high-precision personalized cancer therapy with multimodal nano imaging agents: lead application in image-guided surgery”.

Image paragraph

Creators of a seizure tracking tool that uses devices patients already own and wear. 

Image paragraph

Regular molds have one shape; PinPress is a shape-shifting tool that gives you a thousand molds in one.

Image paragraph

Helping people enjoy the sun with a smart indicator of ultraviolet light that changes colour to warn people of their sun exposure.

The Challenge

In honor of the upcoming Grand Opening of JLABS @ Toronto, Johnson & Johnson Innovation has launched a QuickFire Challenge to award new game-changing early-stage innovation companies with the use of a bench, workstation and access to the JLABS @ Toronto community for one year. In addition, all winners will receive memberships from BIOTECANADA and OBIO , and the Medical Device winner will receive a membership from Medec.

World Without Disease QuickFire Challenge

World Without Disease QuickFire Challenge
World Without Disease QuickFire Challenge
Challenge ended

$ 500,000 + Optional residency at JLABS

Consumer Health
Therapeutics

Winners

Image paragraph

Maryland-based Glyscend, Inc., led by Ashish Nimgaonkar, M.D., Co-founder and CEO, is developing transformative therapies for metabolic diseases (such as type 2 diabetes and obesity) by reducing the concept of bariatric (gastric bypass) surgery into a pill. While type 2 diabetes has traditionally been treated with oral and injectable drugs, these therapies compound over a patient’s lifetime causing weight gain and potentially leading to greater insulin resistance. Bariatric surgery has been shown to have a profound beneficial effect, not only on obesity but also on type 2 diabetes independent of weight loss. Based on the insights from these surgeries, Glyscend is developing the first orally administered intestinal barrier which mimics the intestinal bypass portion of bariatric surgery, thus providing the therapeutic benefits of this surgery in a pill form.

Image paragraph

California-based Neurotrack, led by Elli Kaplan, CEO, is on a mission to transform the diagnosis and prevention of memory loss and related diseases like Alzheimer’s. The company’s product is the Imprint™ Check-Up, a five-minute test that uses eye-tracking technology to assess cognitive decline before symptoms appear. The early diagnosis of memory loss is critical for prevention of cognitive decline and this test is the only tool that can predict memory loss before it starts. In addition, Neurotrack offers a Cognitive Health Program that provides users with tools and advice to make lifestyle changes scientifically proven to reduce the risk of cognitive decline and diseases like Alzheimer’s.

Read More

Read about how innovators are transforming the way illnesses are treated in the most forward-thinking way possible through this challenge: here

Image paragraph

RMIT University’s Micro/Nanomedical Research Center, led by Leslie Yeo, Ph.D., has developed core technology consisting of a portable handheld personalized nebulization platform that enables the aerosolization of drugs for their delivery via inhalation to the lungs. The technology not only offers needle-free administration and the opportunity for systemic delivery of both small and large molecule therapeutics, but also the opportunity for local targeting directly to the lungs, which makes it very attractive for targeting lung diseases, including lung cancer, which is the specific area that represents a critical unmet medical need.

The Challenge

At Johnson & Johnson Innovation and Janssen Research & Development, our goal is to improve the health and wellness of people around the world. To that end, we have a passionate and engaged workforce across our consumer, medical device and pharmaceutical units who are interested in finding and deploying comprehensive, end to end, integrated solutions which take into account the world in which we live today. Johnson & Johnson Innovation and Janssen Research & Development are bringing together the consumer, medical device and pharmaceutical sectors to award $1.5M to the person or team(s) who submits the best idea, technology, or solution that will address a critical health need for the world's population.

Seoul Innovation QuickFire Challenge

Seoul Innovation QuickFire Challenge
Challenge ended

KRW 150,000,000*

Digital Health
Therapeutics

Winners

Image paragraph

GPOWER Inc. is an IoT skincare company providing hardware and software solutions to help monitor, manage and improve skin health.

Company website : www.mybarrierskin.com

Image paragraph

Nu Eyne is a medical device company that focuses on treating ophthalmological disorders, such as dry eye syndrome and eye pain, by applying neuromodulation and tissue engineering.

Company website: www.nueyne.com

The Challenge

Image paragraph

Johnson & Johnson Innovation, JLABS (JLABS) in collaboration with Seoul Metropolitan Government (SMG), Korea Health Industry Development Institute (KHIDI),  Janssen Korea Ltd. and Johnson & Johnson Medical Korea Ltd. have launched the Seoul Innovation QuickFire Challenge to attract global game-changing, early stage innovations. Two winners with the best idea, technology, or solution that will address a health need for the world's population will be a receipt of up to KRW 150,000,000 (approximately US$134,000) in grant funding, entrance to the Seoul Bio Hub (each winner will receive KRW 70,000,000 cash award and a space voucher for KRW 5,000,000 which may be used toward the rent and utilities at the Seoul Bio Hub), and a year of mentorship and coaching.

Rewards and benefits

KRW 150,000,000*
  • *in funding for up to two winners
  • Entrance to the Seoul Bio Hub
  • (*each winner will receive KRW 70,000,000 cash award and a space voucher for KRW 5,000,000 which may be used toward the rent and utilities at the Seoul Bio Hub)
  • A year of mentorship and coaching from Johnson & Johnson Innovation and KHIDI

Areas of interest

This global competition will award the person or team(s) who submits the best idea, technology, or solution focused in the following areas:

  • Health technologies
  • Medical devices
  • Therapeutics

In the following sectors:

  • Bone & join disease
  • Cardiovascular and metabolic disease
  • Immunology
  • Infectious disease
  • Neuroscience
  • Oncology

Why this challenge matters to us

At Johnson & Johnson Innovation, we believe a good idea can come from anywhere, and it’s our goal to find new and innovative technologies that provide solutions to patients from across the world. Working together, we can spark the next great idea that will change the trajectory of health. Seoul, Korea has a robust healthcare innovation ecosystem and Johnson & Johnson is excited to be a part of it through this QuickFire Challenge.

Frequently Asked Questions

What is being awarded and to how many innovators/companies?

Up to two winners will be awarded a combined KRW 150,000,000 & entrance to the Seoul Bio Hub. Each winner will receive KRW 70,000,000 cash award and a space voucher for KRW 5,000,000 which may be used toward the rent and utilities at the Seoul Bio Hub.

Where do I apply?

You can apply through https://jnjawards.fluidreview.com/

Who is eligible to apply?

We encourage applications from everyone interested in the Seoul Innovation QuickFire Challenge from across the globe; however, per the terms and conditions, not all applicants may be eligible to win the Seoul Innovation QuickFire Challenge.

Applicants may be individuals, entrepreneurs, academics, biotech researchers or an early-stage company that is less than 60 months old.

Applicant must not be in default of payment of dues owed to any financial institutions and/or default in payment of any national and/or local taxes in South Korea.

While all potential applicants are encouraged to apply, those that are Health Care Providers (“HCPs”), Government Officials (“GOs”) (see definitions below), which for purposes here include any individual who is a “public official” as defined under the Act on Prohibition of Improper Requests and Provision/Receipt of Money or Valuables, or any organization affiliated with either, will be subjected to additional review, and may not be ultimately eligible to continue with the application and selection process.

Definitions:

Government Official or “GO” means any official or employee of a government agency or instrumentality of the government including but is not limited to a political party, party official or candidate, or public international organizations. It also includes individuals representing himself or herself as a GO, for example, a customs official, inspector, auditor, investigator, elected official, or employee of a government ministry or agency.  Note that this definition includes agents or employees of some non-governmental (NGO) organizations where those organizations perform quasi-governmental services such as distribution of drugs and medical devices or delivery of health care services, an individual who is an agent or consultant to a government agency, or provides a primary business address at a government facility, uses a military title  or rank, supplies an email address associated with a government entity or is otherwise known or believed to be a government employee. Health Ministries and government-owned hospitals often employ HCPs who may be GOs under local law. A private HCP that provides consulting services or otherwise acts as an agent of the government, these individuals should be considered Government Officials. It includes any individual who is a “public official” as defined under the Act on Prohibition of Improper Requests and Provision/Receipt of Money and Valuables of Korea.

“Health Care Provider” or “HCP” means:

  • All physicians; and 
  • Any other individual, institution or entity with the ability to prescribe, acquire or influence the prescription or acquisition of the Johnson & Johnson (including its affiliates and subsidiaries) products or services at issue, and either of the following: 
  • The products at issue are regulated or registered as medicinal products or devices (or their equivalents) in the applicable country; or
  • The products or services at issue are subject to reimbursement by government or third parties; or, are offered for sale with products or services subject to such reimbursement.

Examples of HCPs -- depending on the nature of the products or services at issue -- may include, but are not limited to, doctors, nurses, physician assistants, pharmacists, other para-medical staff, members of product formulary committees, health economists, key opinion leaders including scientists and/or PhD’s, clinical investigators and researchers, administrative and management employees of private and public hospitals, HCPs-in-training and medical societies.

What sectors are you looking for?

Healthcare solutions from across the globe in the following areas::

  • Health technologies
  • Medical devices
  • Therapeutics

In the following sectors:

  • Bone & join disease
  • Cardiovascular and metabolic disease
  • Immunology
  • Infectious disease
  • Neuroscience
  • Oncology
What are the specific criteria for application?

All applicants must outline their interest in Seoul, South Korea, including plans to work in Seoul and engage with the local ecosystem as well as how the mentorship can critically support their innovation. Applicants may be individuals, entrepreneurs, academics, biotech researchers or an early-stage company that is less than 60 months old and must not be in default of payment of dues owed to any financial institutions and/or default in payment of any national and/or local taxes in South Korea.

Do applicants have to reside in Korea in order to apply?

No, this is a global challenge. However, if selected as a winner or finalist, at least one core team member of the applicant company must reside in the Seoul Bio Hub for no less than 1 year (each winner will receive a space voucher for KRW 5,000,000 which may be used toward the rent and utilities at the Seoul Bio Hub).

Can I submit supporting documents (for example a video) as part of my application?

You will have the opportunity and are encouraged to upload supporting materials such as slide decks, research papers, and videos as part of your application. You may submit a video along with your typed responses. Maximum length is 2 minutes.

Is it ok if some of the information I submit is confidential?

Do not submit confidential information. Only non-confidential information should be submitted.

*For further information on eligibility for this QuickFire Challenge, please refer to the Terms & Conditions presented in your application form.

Application process

Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Potential impact
  • Uniqueness of solution & level of competition in current market
  • Quality & feasibility of technology
  • Team credibility & capabilities
  • Clarity of plan: Milestones for the next 12 months
  • Idea submission outlines interest in the innovation ecosystem in Seoul, South Korea

Deadline to apply is September 29, 2017
Winner(s) will be announced in December.

Timeline

KST
Applications Open
KST
Submission Deadline
KST
Judging Process Begins
KST
Winners Announced at Seoul Bio Hub

About Johnson & Johnson Innovation

Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation - JLINX, Johnson & Johnson Innovation – JJDC and our Business Development teams to create customized deals and novel 4 collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.

 

About Johnson & Johnson Innovation, JLABS

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.


JLABS currently has nine locations in innovation hot spots across North America and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto and a new JLABS @ NYC (in collaboration with the New York Genome Center -opening in 2018).  For more information about JLABS, please visit www.jlabs.jnjinnovation.com.

 

About Janssen Pharmaceutical Companies

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com/korea .


About the Johnson & Johnson Medical Devices Companies

The Johnson & Johnson Medical Devices Companies’ purpose is to reach more patients and restore more lives. Having advanced patient care for more than a century, these companies represent an unparalleled breadth of products, services, programs and research and development capabilities in surgical technology, orthopaedics, cardiovascular and specialty solutions with an offering directed at delivering clinical and economic value to health care systems worldwide.

 

About Seoul Metropolitan Government (SMG)

Seoul is a global city located at the center of Northeast Asia characterized by easy access to metropolitan cities around the world and convenient living conditions, particularly with nine (9) subway lines, 6,000 bus stops, and 22 international schools.

The Seoul Metropolitan Area is an optimal location to foster technology-oriented venture firms as it houses more than 20,000 research institutes, 139 universities, and 133 general hospitals, concentrating top-caliber workforce and technology in a single location.

The Hongneung Biomedical Cluster, home to Seoul Bio Hub, which is slated to open in september 2017, houses national research institutes (KIST,etc.), research-oriented hospitals, and universities. The Seoul Metropolitan Government plans to offer facilities and equipment for the fast growth of technologically advanced startups and help businesses, researchers, and businessmen develop and commercialize innovative technologies via support in investment, administration, and information services.

 

About Korea Health Industry Development Institute (KHIDI)

KHIDI is a government-affiliated institution which performs professional and systematic support to develop domestic healthcare industry and enhance healthcare services. Since its establishment in 1999, KHIDI has led expansion of healthcare research and development investment and building competitiveness of Korea's healthcare industry, i.e., health services, pharmaceuticals, medical devices, food and beauty-cosmetic. KHIDI is designated as an operating body of Seoul Bio Hub, and plans to utilize its infrastructure and network to facilitate cooperation with relevant stakeholders. For more information, please visit http://www.khidi.or.kr/eps.

 

About Seoul Bio Hub

Seoul Bio Hub, located in northern Seoul and slated to begin operations in September 2017, is a life science innovation center sponsored by SMG and operated by KHIDI. The key function is to support early stage life science companies’ growth and commercialization by providing full-service wet laboratory and office spaces, shared equipment, networking events, training programs, and investor relation opportunities. As the only biotech startup platform located in Seoul, it leverages its geographical advantages to accelerate the startup ecosystem, by facilitating cooperative networks among research-driven hospitals, universities, national research institutes, and venture capitals within close vicinity. For more information, please visit http://www.seoulbiohub.kr.

bottom-banner-version-5.png

 

You can find our press release here.

Richard Mason named Head of Johnson & Johnson Innovation, London.


We are delighted to announce Dr. Richard Mason will be joining Johnson & Johnson Innovation on November 3rd to head our London Innovation Centre.
Richard brings a dynamic background of relevant experience as an entrepreneur, physician, and business leader.

Richard is a UK native and brings a strong connection to the biotech, government and academic communities within London, the UK and throughout Europe. Richard most recently served as Chief Executive Officer of XO1 Ltd, which was acquired through a Johnson & Johnson Innovation-facilitated deal in March of this year.  

Prior to his role at XO1-Limited, Richard was Head of Strategy and Business Development at specialty pharmaceutical company BTG Plc, where he devised the strategy for BTG to become a profitable interventional medicine/medical device-focused company, and led its execution through the acquisition of commercial-stage businesses worth over $730m (Biocompatibles, TheraSphere, Ekos Corp). Richard also served in senior management positions for Advent Venture Partners LLC, where he was an interim CEO for several portfolio companies, and at Cambridge Antibody Technology Plc (CAT) where he led business development. 
"In my previous role as CEO of XO1, I had the pleasure of getting to know Johnson & Johnson Innovation, and Janssen, very well during the acquisition process and subsequent integration of XO1," said Richard. "What impressed me so much was how Johnson & Johnson has created a really dynamic environment where entrepreneurial people can make great things happen, and quickly, even though they are part of one of the largest companies in the world." 
In collaboration with their internal partners at JJDC, R&D, business development, and other global innovation centres, Richard and the London Innovation team will work to continue to identify promising early-stage healthcare solutions in Europe in pharmaceuticals, medical devices and consumer healthcare.  Richard assumes the role from predecessor Patrick Verheyen who was recently appointed as Head, Janssen Business Development.
Richard lives near Cambridge, UK. He is married to Angela, who trained as a family doctor, and they have three children. In his spare time he loves running, skiing, is a pilot, and a member of the British Army Reserve. With a true entrepreneurial spirit, a team-focused approach and genuine expertise in value creation through unique collaborations, Richard's appointment signifies a truly exciting milestone for the London Innovation Centre.
 

Richard will play a crucial role in working with the London IC Team to identify and develop outstanding science and transformative medicines, devices and consumer products. Richard joins the team after successfully working with Johnson & Johnson Innovation as a collaborator under his capacity as the Chief Executive Officer of XO1-Limited which was acquired by Johnson & Johnson earlier this year.
 

 

Type
Articles

Lone Star State of Mind

Growing up in the northeast, I’ve always held certain preconceived notions about Texas. I’ve heard many of the quotes: “Everything is bigger in Texas," “Don’t mess with Texas," and “You may all go to hell, but I will go to Texas." I’ve watched Friday Night Lights and have seen a few episodes of “Fixer Upper." Pop culture aside, from an industry perspective, Houston seemed to have a handle on the energy sector, and Austin was emerging as a technology hub, but for biotech, I never found a reason to take a second look.

HIPHN_JLABS@TMC

I’ve been working at Johnson & Johnson Innovation for the past three years, and since the opening of a JLABS at the Texas Medical Center one year ago today, innovative projects and news from Houston continued to pop up in my inbox. Not only was JLABS @ TMC the first JLABS with a prototyping lab for medical devices, but with its proximity to research powerhouses like MD Anderson, and deep academic institutions such as Baylor and Methodist, Houston began to emerge on my radar as a true potential hub for biotech innovation.

The growth we’ve experienced at JLABS @ TMC over the past 12 months is proof enough that life sciences –including biotech and medtech – is booming in Houston. In just one year, we have grown to house over 30 companies; pushing us to almost 70 percent capacity. Our residents have raised millions of dollars in venture financing, received FDA fast track and orphan drug designations, and continue to gain interest from leading physicians and researchers around the world for their scientific advancements.

With a mix of therapeutics, medical device, and digital health covering verticals from oncology to cardiovascular and even food sciences, JLABS @ TMC houses one of the most diverse portfolios across all of Johnson & Johnson Innovation. We’re getting new inquiries weekly, and with the upcoming launch of the Center for Device Innovation (CDI @ TMC), Houston is poised to become a world leading innovation hub for bio and life sciences.

The opportunity to step in as Head of JLABS @ TMC is an exciting one, and to throw out one final quote from Sam Houston, “I wasn’t born in Texas, but I got here as fast as I could."

Type
Articles

Bringing Your Whole Self to Work

At Johnson & Johnson Innovation, JLABS (JLABS), bringing your “whole self” to work isn’t an option, it’s a mandate!  And that’s why I love working in this environment.  I have worked in the communications business for years, and remember well when diversity and inclusion weren’t discussed and most certainly not encouraged in the workplace.  Working in that kind of environment is not only detrimental to an individual who may feel marginalized and unappreciated, it also has adverse effects on the entire organization. 

Allowing people to bring their whole selves to work means they are free to be who they are (regardless of race, color, religion, sexual orientation or gender identity), which leads to a more productive individual. When people feel comfortable, accepted and valued in their work environment, they become more productive, which in turn creates a more productive overall workplace, where ideas can flow freely, and creativity at solving business challenges helps move a business forward in ways you couldn’t imagine. 

The possibilities are truly limitless when individuals aren’t constrained, and they feel their views are considered equally in the eyes of their peers and management.  At JLABS, it starts at the top!  We are all encouraged to bring our whole selves, our true selves to the table, to take risks, with no idea being too small or too big to be considered. This commitment empowers our team and the positive work environment directly correlates to why we’ve grown exponentially across the US and Canada in five short years. We’re continuously encouraged to ask “why not?”  instead of “why,” which gives us a different perspective and freedom to solve challenges in creative ways. We’re given the space to think outside the box, find the best way to attack complex problems and encouraged to be the best we can be and to build the organization to be the best it can be.

It sounds like pretty simple, straight-forward stuff, and something that every organization should do. Unfortunately, not all companies and industries support this same open, encouraging environment. In the healthcare industry, we don’t have the luxury of time when it comes to bringing solutions to patients in need, so it becomes even more critical to find new, innovative ways of bringing creative healthcare ideas from concept to consumer to address the most significant health challenges we face today.

For me, LGBTQ Pride month is a time for reflection on how far we’ve come as a society and in the workplace in accepting and embracing our differences as human beings. It’s always heartening to know that there are so many people who appreciate and accept those differences. We can’t let prejudice interfere with the important work at hand -- In our case, delivering on what patients demand from the largest healthcare company in the world.

The opportunity I have been given –to make a difference every day—doesn’t exist everywhere, but hopefully, someday it will.  For now, I consider myself lucky to be part of such an accepting organization and to participate, in some small way, in making a difference in people’s lives by helping to build something truly special at JLABS.

By: Christopher Lalli – Communications, Johnson & Johnson Innovation, JLABS

Type
Articles